OMDA at a glance
Omada Health, Inc. (OMDA, SEC CIK 1611115) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Omada Health, Inc. (OMDA) reported revenue of $260.2 million (up 53.2% from FY2024) and a net loss of $12.8 million. Diluted EPS was -$0.35.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Omada Health, Inc. (OMDA) shares worth $449.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Duffy Sean P. on November 4, 2026 of 12,944 shares at $19.22 per share.
- In the last 90 days, OMDA insiders reported 0 open-market purchases ($0) and 15 open-market sales ($1.7M) on Form 4, a net sale of $1.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $260.2M
- +53.2% vs prior year
- Insiders · 90 days
- 0 buys · 15 sells
- Net −$1.7M
- 13F holders
- 24 funds
- $449.1M · +1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added AI risk: December 2025 Executive Order and March 2026 framework create uncertainty over state-law preemption and compliance costs
- Regulatory risk: evolving AI requirements may force platform redesign, increase expenses, and trigger claims or enforcement
- Competitive risk: AI-native healthcare offerings may deliver care at lower operating cost and reduce demand for Omada programs
- Customer concentration: top five health plan and PBM partners generated 78% of nine-month 2026 revenue, including Cigna affiliates
- Financial risk: accumulated deficit reached $447.9 million as of September 30, 2026 despite nine-month net income of $8.9 million
Management Discussion & Analysis
- Q3 revenue $91.3M, up 34% YoY from $68.0M, driven by services revenue of $85.1M, up 35%
- Gross margin increased 10 percentage points YoY, with gross profit $69.3M versus $45.1M
- Services best-performing line, up $22.2M YoY; hardware revenue $6.2M, up 22% to $5.1M
- Nine-month operating cash flow $7.3M versus $(3.1)M, with $4.9M invested in software and equipment
- Cash and equivalents $243.2M; tariff-related device costs and rising GLP-1 affordability pressures remain headwinds
AI summary of the OMDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Omada Health announced financial results for the three months ended September 30, 2026
- Full revenue, profitability, and guidance details are in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Q3 revenue $91.3M, up 34% year over year, with services revenue driving growth at $85.1M
- GAAP gross margin expanded to 76% from 66%, while net income reached $6.6M versus a $3.2M loss
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results announced for the three months ended June 30, 2026
- Investor-relevant financial figures and management commentary are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $87.8M, up 43% year over year, with total members up 45%, signaling strong demand and enrollment momentum
- Gross margin reached 73% from 66%, while adjusted EBITDA rose to $10.8M from a $0.2M loss, marking meaningful operating leverage
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO transition effective January 1, 2027: President Wei-Li Shao succeeds Sean Duffy
- Duffy becomes Executive Chairman, preserving founder-level leadership and strategic continuity
Item 5.07: Submission of Matters to a Vote of Security Holders
- Sean Duffy and Trevor Fetter reelected as Class I directors through the 2029 annual meeting
- Duffy received 18,540,089 votes for and Fetter 18,538,042, with 13,920,625 broker non-votes each
AI summaries of OMDA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OMDA
Don't miss the next OMDA filing
- Alerts as it files. A push when OMDA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OMDA, by share count.
- Ask anything. An AI agent that reads every OMDA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Duffy Sean P. | Sell | Nov 4, 2026 | 12,944 | $19.22 |
| Duffy Sean P. | M | Nov 4, 2026 | 12,944 | - |
| Duffy Sean P. | M | Nov 4, 2026 | 12,944 | $5.82 |
| HILLEMAN JERYL L | A | Oct 5, 2026 | 1,214 | - |
| FETTER TREVOR | A | Oct 5, 2026 | 751 | - |
| Klapstein Julie D | A | Oct 5, 2026 | 549 | - |
| ROOT JONATHAN D | A | Oct 5, 2026 | 694 | - |
| Duffy Sean P. | M | Oct 1, 2026 | 4,314 | $8.28 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $169.8M | $260.2M |
| Gross Profit | - | $102.9M | $170.9M |
| Operating Income | - | -$43.7M | -$12.0M |
| Net Income | - | -$47.1M | -$12.8M |
| Gross Margin | - | 60.6% | 65.7% |
| Op. Margin | - | -25.7% | -4.6% |
| Net Margin | - | -27.8% | -4.9% |
| Balance Sheet | |||
| Total Assets | - | $150.9M | $305.4M |
| Equity | -$350.1M | -$384.4M | $229.7M |
| ROE | - | 12.3% | -5.6% |
| Per Share | |||
| EPS | - | $-6.11 | $-0.35 |
| Cash Flow | |||
| Operating CF | - | -$34.2M | $18.3M |
| CapEx | $416K | $596K | $1.3M |
Source: XBRL data in Omada Health, Inc. (OMDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OMDA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $449.1M |
| Q2 2026 | 23 | $364.6M |
| Q1 2026 | 22 | $162.3M |
| Q4 2025 | 18 | $184.3M |
| Q3 2025 | 16 | $157.0M |
| Q2 2025 | 12 | $130.1M |
- D.E. Shaw & Co+1.77M (+147%)
- BlackRock+1.54M (+69%)
- JPMorgan Chase & Co+857.4K (+285%)
- State Street Corp+617.4K (+101%)
- Vanguard Capital Management LLC+528.6K (+27%)
- Millennium Management−316.8K (-18%)
- T. Rowe Price Group−72.0K (-36%)
- Franklin Resources−30.1K (-38%)
- Wells Fargo & Co−17.9K (-53%)
- Bank of America Corp−14.6K (-5%)
- FMR LLC (Fidelity)−2.78M
Source: 13F-HR filings on SEC EDGAR (aggregated from 115 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OMDA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 6, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
Related Health Care companies
- DCGO · DocGo Inc.Services-Health Services
- WGS · GeneDx Holdings Corp.Services-Health Services
- INNV · InnovAge Holding Corp.Services-Health Services
- LFST · LifeStance Health Group, Inc.Services-Health Services
- PNTG · Pennant Group, Inc.Services-Health Services
- PRVA · Privia Health Group, Inc.Services-Health Services
- SRTA · Strata Critical Medical, Inc.Services-Health Services
- TALK · Talkspace, Inc.Services-Health Services
OMDA SEC filings: frequently asked questions
Are OMDA insiders buying or selling?
In the last 90 days, Omada Health, Inc. (OMDA) officers, directors and 10% owners reported no open-market purchases and 15 open-market sales worth $1.7 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OMDA stock?
As of September 30, 2026, the largest Omada Health, Inc. (OMDA) holders among the 13F filers tracked by SignalX were BlackRock ($78.3 million), Morgan Stanley ($67.4 million), D.E. Shaw & Co ($61.8 million), Vanguard Capital Management LLC ($51.1 million), Millennium Management ($29.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OMDA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Omada Health, Inc. (OMDA) reported revenue of $260.2 million (up 53.2% from FY2024) and a net loss of $12.8 million. Diluted EPS was -$0.35. The figures come from the XBRL data in the 10-K.
What did OMDA report in its latest 8-K?
Omada Health, Inc. (OMDA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Omada Health announced financial results for the three months ended September 30, 2026.
What are the latest OMDA SEC filings?
Omada Health, Inc. (OMDA) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 6, 2026.
What is OMDA's SEC CIK number?
Omada Health, Inc. (OMDA)'s SEC Central Index Key (CIK) is 1611115. EDGAR lists every OMDA filing under that number.
Ask anything about OMDA
The research agent reads OMDA's filings, financials, insider trades and 13F holders, then answers with sources.